1
项与 Anti-GD2|NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) 相关的临床试验GD2/CD56 Bi-specific CAR-T Cells for Cancer Treatment
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CAR-T cells and their persistency in patients.
100 项与 Anti-GD2|NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) 相关的临床结果
100 项与 Anti-GD2|NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) 相关的转化医学
100 项与 Anti-GD2|NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) 相关的专利(医药)
100 项与 Anti-GD2|NCAM1 CAR-T (Shenzhen Geno-Immune Medical ) 相关的药物交易